Bharat Serums emphasizes on novel products
Bharat Serums and Vaccines manufactures and markets biological, pharmaceutical and biotechnology products and  is now looking at European market for its expansion.

The past fiscal saw  Bharat Serums  and Vaccines (BSV) remaining stable and clocking the same annual revenues of Rs 140 crore for fiscal 2007-08. The company manufactures and markets biological, pharmaceutical and biotechnology products and  has in its portfolio over 25 brands. Its product range includes plasma derivatives, monoclonals, equine antitoxins and serums, cardiovascular, antimicrobials, antifungals, anaesthetics and hormones. Over the years, BSV has given emphasis to its R&D  operations both in India and overseas. The company has three distinct R&D divisions  working extensively on novel drug delivery system (NDDS), bioetchnology and equine products.
In 2008, BSV announced that it has developed a novel formulation of Docetaxel which is free from surfactant Polysorbate-80. This formulation could potentially be a breakthrough in avoiding the fluid retention/hypersensitivity and extravasation reactions which are associated with Taxotere. Initial preclinical studies have shown a higher safety and a superior pharmacokinetic profile when compared to Taxotere. Efficacy in tumor bearing mice has also been established for the newly developed formulation. Taxotere, a branded formulation of Docetaxel, is marketed by Sanofi Aventis with global sales of more than Rs 13,624 crore ($2.9 billion). BSV had earlier developed a novel liposomal formulation of doxorubicin for which it tied up with a leading Indian pharmaceutical company. Recently, BSV has entered into licensing agreement with Actavis, one of the world’s leading generic pharmaceutical companies for an anti-infective product. BSV is in exploratory discussions with pharmaceutical companies for collaboration in commercializing the novel formulation of Docetaxel for various worldwide markets.
BSV, one of the top ten Indian biopharmaceutical companies, has entered into an exclusive licensing , manufacturing and supply agreement with Actavis for marketing of one of its anti-infective generic formulations. Under the terms of the agreement, BSV will develop and manufacture the product for marketing by Actavis in Europe, Australia, South Africa and Turkey. The product is a sterile lyophilized injection that pose significant technological and regulatory challenges. The total worldwide sales of the product are close to Rs 1,408 crore ($300 million).
BSV and Actavis will be working closely together to obtain the marketing authorization in Europe and other countries.